An Investigation of Safety and Tolerability of NNC0114-0006 in Subjects With Systemic Lupus Erythematosus (SLE)

NCT01689025 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

10

Enrollment

INDUSTRY

Sponsor class

Conditions

Inflammation
Systemic Lupus Erythematosus

Interventions

DRUG: NNC0114-0006
DRUG: placebo

Sponsor

Novo Nordisk A/S